HDAP Overview


The Massachusetts HIV Drug Assistance Program (HDAP) provides access to HIV-related medications for residents of the Commonwealth of Massachusetts who cannot afford to pay the full cost of these vital drugs.

HDAP is a program of the Office of HIV/AIDS within the Massachusetts Department of Public Health, funded through federal and state sources, including the U.S. Public Health Service/Health Resources and Services Administration and the Boston Public Health Commission AIDS Program through Title I of the Ryan White CARE Act. HDAP is administered by Community Research Initiative of New England (CRI).

By law, HDAP is a “payer of last resort”; this means program enrollees must provide proof that they have applied to other entitlement programs (e.g., Medicaid, MassHealth, Medicare, etc.) at the time of their HDAP application.

HDAP plays a crucial role in providing resources to a diverse population that may otherwise lack access to HIV-related medications and/or health insurance. More than half of HDAP enrollees are from communities of color, and approximately three-quarters of HDAP clients have incomes of less than 200% of the federal poverty level ($24,280).


In order to be eligible for HDAP, an individual must be HIV-positive and living in Massachusetts. Undocumented Massachusetts residents are eligible to enroll in HDAP.

To enroll, an individual must also meet income eligibility guidelines, which are set at a level that recognizes both the cost and number of HIV-related medications an individual with HIV/AIDS may need, as well as the high cost of living in Massachusetts. Individuals with annual incomes of up to 500% of the federal poverty level ($60,700 as of January 22, 2018, with an allowance of $4,320 per dependent) are eligible to enroll.


HDAP is among the nation’s most complete drug assistance programs for people living with HIV. HDAP can pay for medications and drug copays, private non-group health insurance premiums and premium copays, HIV resistance testing (genotype and virtual phenotype lab tests), and post-exposure prophylaxis (PEP) for potential nonoccupational exposures to HIV.

For more information, please call CRI at 617.502.1700.